이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

실로시빈의 행동 효과에 대한 RECAP 2

2026년 11월 3일 업데이트: University of Wisconsin, Madison

실로시빈의 행동 효과에 대한 경험, 의식적 인식 및 가소성의 역할 - 후속 연구(RECAP 2 연구)

The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing.

Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing.

Participants will:

  • Receive one of four possible combinations of medications
  • Undergo an MRI
  • Complete questionnaires
  • Undergo transcranial magnetic stimulation (TMS) and EEG
  • Volunteer for an open-label follow-up phase of study

연구 개요

상세 설명

The purpose of this study is to investigate the role that inducing neuroplasticity plays in the behavioral effects of psilocybin in people with modest decrements in emotional wellbeing.

연구 유형

중재적

등록 (추정된)

60

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Wisconsin
      • Madison, Wisconsin, 미국, 53792
        • 모병
        • UW School of Medicine and Public Health

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age 18 to 65 years at screening, of any identified gender and racial/ethnic group
  • Physically healthy; does not meet criteria for an exclusionary medical condition
  • English-speaking (able to provide consent and complete questionnaires)
  • Modest decrement in self-reported wellbeing without the presence of a DSM-5 Axis I mood or anxiety disorder
  • Able to undergo magnetic resonance imaging (MRI) and transcranial magnetic stimulation (TMS)

Exclusion Criteria:

  • Exclusionary DSM-5 psychiatric diagnosis and/or active suicidal ideation
  • Exclusionary medical conditions
  • Clinically significant safety lab abnormalities (i.e., Complete Blood Count with Differential, Comprehensive Metabolic Panel, and urinalysis)
  • Clinically significant electrocardiogram (ECG)
  • Use of psychotropic or CNS-altering medications within 3 months of screening
  • Hypertension or tachycardia

Participants invited to participate in the 28-day open label follow-up phase will:

  1. Fully complete all activities associated with the randomized phase, including the virtual Day 84 assessment, before being approached about participation in the open label phase.

  2. Participants who meet stopping criteria during the randomized phase are not eligible to enroll in the open label phase.

  3. Participants who withdraw from the randomized phase are not eligible to enroll in the open label phase.

  4. Enrollment into the open label phase must occur in the following sequence:

    1. participants who have fully completed the randomized phase are screened for eligibility;
    2. eligible participants meet with the study team and provide informed consent for the open label phase;
    3. baseline eligibility is reassessed to confirm that participation in the open label phase remains appropriate and safe.

The Principal Investigator may decline or defer open-label enrollment when unresolved concerns make participation unsafe or scientifically inappropriate.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 기초 과학
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Group 1: Psilocybin and intravenous (IV) midazolam

Psilocybin (25 mg) + IV midazolam

25mg of psilocybin

다른 이름들:
  • 실로시빈

1mg of psilocybin

다른 이름들:
  • 실로시빈

The goal of the midazolam dosing regimen is to induce amnesia of the psychedelic experience without inducing over-sedation during the dosing session.

실험적: Group 2: Psilocybin and IV saline

Psilocybin (25 mg) + IV saline (placebo for midazolam)

25mg of psilocybin

다른 이름들:
  • 실로시빈

1mg of psilocybin

다른 이름들:
  • 실로시빈

Saline will be administered as a placebo for midazolam

실험적: Group 3: Psilocybin and IV midazolam

Psilocybin (1 mg/control) + IV midazolam

25mg of psilocybin

다른 이름들:
  • 실로시빈

1mg of psilocybin

다른 이름들:
  • 실로시빈

The goal of the midazolam dosing regimen is to induce amnesia of the psychedelic experience without inducing over-sedation during the dosing session.

실험적: Group 4: Psilocybin and IV saline

Psilocybin (1 mg/control) + IV saline

25mg of psilocybin

다른 이름들:
  • 실로시빈

1mg of psilocybin

다른 이름들:
  • 실로시빈

Saline will be administered as a placebo for midazolam

실험적: Exploratory Open Label Follow-Up Phase

Psilocybin (25 mg)

25mg of psilocybin

다른 이름들:
  • 실로시빈

1mg of psilocybin

다른 이름들:
  • 실로시빈

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in Warwick-Edinburgh Mental wellbeing Scale (WEMWBS)
기간: Baseline to 7 days post-dose

WEMWBS is a 14-item questionnaire in which participants describe their experience of each item. It is scored on a 5-point Likert scale, possible range of 14-70 where higher scores indicate higher levels of wellbeing.

Baseline to 7 days post-dose
Change in Brief Experiential Avoidance Questionnaire (BEAQ)
기간: Baseline to 7 days post-dose

The BEAQ is a 15-item questionnaire assessing participants agreement with wellbeing statements. It is scored on a 6-point Likert scale, ranging from 15-90 with higher scores indicating a greater tendency towards experiential avoidance

Baseline to 7 days post-dose
Change in Probabilistic Reversal Learning (PRL)
기간: Baseline to 7 days post-dose

Participants are presented with two stimuli or options and learn which one is more likely to be associated with a reward based on feedback after each trial. After a certain number of trials, the reward contingencies are reversed, meaning the previously advantageous option becomes less likely to be rewarded, and vice versa. The task assesses how quickly and effectively individuals can adapt to these changes in reward contingencies. Researchers analyze various performance metrics, such as the speed of reversal, the number of errors, and the patterns of choices (e.g., win-stay, lose-shift).

Baseline to 7 days post-dose
Change in transcranial magnetic stimulation evoked potential (TEP) amplitude
기간: Baseline to 7 days post-dose

TEP measures neural excitability in the stimulated region of the brain.

Baseline to 7 days post-dose

2차 결과 측정

결과 측정
측정값 설명
기간
Change in WEMWBS
기간: Baseline to 28 days post-dose

WEMWBS is a 14-item questionnaire in which participants describe their experience of each item. It is scored on a 5-point Likert scale, possible range of 14-70 where higher scores indicate higher levels of wellbeing.

Baseline to 28 days post-dose
Change in BEAQ
기간: Baseline to 28 days post-dose

The BEAQ is a 15-item questionnaire assessing participants agreement with wellbeing statements. It is scored on a 6-point Likert scale, ranging from 15-90 with higher scores indicating a greater tendency towards experiential avoidance

Baseline to 28 days post-dose
Change in PRL
기간: Baseline to 28 days post-dose

Participants are presented with two stimuli or options and learn which one is more likely to be associated with a reward based on feedback after each trial. After a certain number of trials, the reward contingencies are reversed, meaning the previously advantageous option becomes less likely to be rewarded, and vice versa. The task assesses how quickly and effectively individuals can adapt to these changes in reward contingencies. Researchers analyze various performance metrics, such as the speed of reversal, the number of errors, and the patterns of choices (e.g., win-stay, lose-shift).

Baseline to 28 days post-dose
Change in TEP amplitude
기간: Baseline to 28 days post-dose

TEP measures neural excitability in the stimulated region of the brain.

Baseline to 28 days post-dose
Altered States of Consciousness (ASC) questionnaire
기간: Dosing 1 day

Participants will complete a selection of several questions from the ASC questionnaire that strongly associate positively or negatively with later antidepressant effect of psilocybin in patients with treatment resistant depression or capture classic features of the psychedelic experience. During the dosing session, investigator will repeatedly ask selected items from the ASC scale to get a "real time" measure of what the participants are experiencing. Each of these items will be scored separately. Higher score are indicative of a more intense psychedelic experience.

Dosing 1 day
Emotional Breakthrough Inventory (EBI)
기간: Dosing 1 day

The EBI is a 6-item scale that assesses the presence and severity of emotionally challenging/distressing experiences that occur during a psychedelic experience. Participants rate to what extent the statements apply to their experience by marking a single line across each scale. Scale ranges from not at all to very much so. Higher scores (more slashes toward the 'very much so' end) on the scale have been associated with enhanced well-being following psychedelic use

Dosing 1 day
Psychological Insight Questionnaire (PIQ)
기간: Dosing 1 day

The PIQ is a 23-item instrument designed to query self-perceived attainment of insight during a psychedelic medicine session. Items are rated on a 6-point Likert scale, 0 = no not at all and 5 = extremely. Possible scares range from 0-115, with higher scores indicating greater insight.

Dosing 1 day

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Charles Raison, MD, University of Wisconsin, Madison

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 8월 7일

기본 완료 (추정된)

2027년 12월 1일

연구 완료 (추정된)

2027년 12월 1일

연구 등록 날짜

최초 제출

2024년 11월 14일

QC 기준을 충족하는 최초 제출

2024년 11월 15일

처음 게시됨 (실제)

2024년 11월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 3일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2024-0852
  • A538900 (기타 식별자: UW- Madison)
  • SMPH/PSYCHIATRY/PSYCHIATRY (기타 식별자: UW- Madison)
  • Protocol Version 9/30/2026 (기타 식별자: UW- Madison)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다